stay updated with our newsletter

Subscribe
Facebook Twitter Linkedin

Kim Stewart

Integrative Psychiatry Effective but Overlooked for Cancer Patients

Nearly three-quarters of cancer patients who have major depression are not currently receiving treatment for depression, and that a new integrated treatment programme is strikingly more effective at reducing depression and improving quality of life than current care, according to three papers published in The Lancet Psychiatry, The Lancet, and The Lancet Oncology. Lead author Professor Michael Sharpe from the University of Oxford in the UK, says “The huge benefit that DCPC delivers for patients with cancer and depression shows what we can achieve for patients if we take as much care with the treatment of their depression as we do with the treatment of their cancer.” By M Sharpe, et al., published in the Lancet and Lancet Oncology, Aug. 2014.

Hispanic Men Most Affected by Diabetes Epidemic

Close to half (40%) of the adult population of the USA is expected to develop type 2 diabetes at some point during their lifetime, suggests a major study published in The Lancet Diabetes & Endocrinology. The future looks even worse for some ethnic minority groups, with one in two (> 50%) Hispanic men and women and non-Hispanic black women predicted to develop the disease. A team of US researchers combined data from nationally representative US population interviews and death certificates for about 600 000 adults to estimate trends in the lifetime risk of diabetes and years of life lost to diabetes in the USA between 1985 and 2011.

Put the Script Pad Down: FDA’s New Drug Approvals Pose Significant Risks

chronic inflammation

For every 100 new drugs introduced in the market, there have been 34 withdrawals or new black box warnings in the past 25 years. Since 1992, FDA sped up the pace and approval process for pharmaceutical companies willing to pay a fee. Approval time was cut in half, but with it came a significant number of safety withdrawals and warnings. This study, released today in Health Affairs, shows the expeditious process has placed millions of Americans at risk, essentially making them unwitting members of safety trials after the drug was approved.

Omega-3 & ALA Fatty Acids May Reduce Lou Gehrig’s Disease Risk

Omega-3 fatty acids may play a role in cutting one’s risk of fatal neurodegenerative disease amyotrophic lateral sclerosis (ALS) by one third, a new study suggests from the Harvard School of Public Health in Boston. The research suggests that EFA’s could be part of prevention or integrative therapeutic treatment for ALS. By Kathryn C. Fitzgerald, M.Sc, JAMA Neurology, July 2014.

Citicoline Improves Teen/Adult Attention in Two Trials

In an age where attention spans are short and activity levels are low for teen boys, a new study shows citicoline may improve concentration and motor speed. The randomized, double-blinded, placebo-controlled human clinical trial conducted by The Brain Institute, at the University of Utah, was presented at the annual AmericanRead

New Theory on Atherosclerosis: Massively Calcified Endosome Death

Anti-Inflammatory Function of HDL Cholesterol
Larry Weisenthal, M.D., Ph.D., announced today (July 22) new unpublished findings that may lead to a better understanding on the cause of atherosclerosis. Dr. Weisenthal, a physician and researcher, says he discovered a previously unknown biological mechanism that accounts for vascular calcification, or hardening of the arteries. Dr. Weisenthal has

Read more

Webinar: A Genomic Approach To Cardiovascular Disease

COVID and cardiovascular complications

Webinar by Genoma International. Sherry is a 53 year-old female with a family history of cardiovascular disease. She was proactive about her approach to health, physically active, and ate a balanced diet. When she was found to have significantly elevated LDL cholesterol on a routine checkup, she switched to a completely plant-basedRead